Join

Compare · MOH vs OPGN

MOH vs OPGN

Side-by-side comparison of Molina Healthcare Inc (MOH) and OpGen Inc. (OPGN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MOH and OPGN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • MOH is the larger of the two at $16.65B, about 433.9x OPGN ($38.4M).
  • Over the past year, MOH is down 45.1% and OPGN is up 0.0% - OPGN leads by 45.1 points.
  • MOH has hit the wire 3 times in the past 4 weeks while OPGN has been quiet.
  • MOH has more recent analyst coverage (25 ratings vs 0 for OPGN).
PerformanceMOH-1.39%OPGN+0.00%
2026-01-02+0.00%2026-04-24
MetricMOHOPGN
Company
Molina Healthcare Inc
OpGen Inc.
Price
$175.91+0.84%
$1.96-14.04%
Market cap
$16.65B
$38.4M
1M return
+25.82%
+0.00%
1Y return
-45.10%
+0.00%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2003
2015
News (4w)
3
0
Recent ratings
25
0
MOH

Molina Healthcare Inc

Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2020, it served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 15 states. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.

OPGN

OpGen Inc.

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.